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Received March 21, 2012; accepted October 11, 2012AbstractBackground: Patients with polycystic ovary syndrome (PCOS) have an increased prevalence of thrombophilia, leading to higher rates of
pregnancy loss. The aim of this study was to determine the association between thrombophilia and recurrent pregnancy loss (RPL) in patients
with and without PCOS.
Methods: In this comparative caseecontrol study, we included 60 patients with RPL (3 consecutive pregnancy losses at <20 weeks of
gestation) and PCOS (Group 1), 60 patients with PCOS and without RPL (Group 2), 60 patients with RPL and without PCOS (Group 3), and 60
healthy individuals (Group 4). These four study groups were compared regarding serum levels of testosterone, fasting insulin, homocysteine
(Hcy), plasminogen activator inhibitor activity (PAI-Fx), protein C, protein S, antithrombin III, activated protein C ratio (APCR), factor V
Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase gene mutations.
Results: Patients in Group 1 had significantly higher levels of testosterone ( p ¼ 0.026), dehydroepiandrosterone sulfate ( p ¼ 0.035), fasting
insulin ( p ¼ 0.015), Hcy ( p ¼ 0.036), and PAI-Fx ( p ¼ 0.008) compared to Group 3. They also had higher proportions of APCR ( p ¼ 0.009)
and a higher prevalence of factor V Leiden mutations compared to Group 3 ( p ¼ 0.001). However, there was no significant difference in protein
C ( p ¼ 0.088), protein S ( p ¼ 0.514), or antithrombin III ( p ¼ 0.627) between the four study groups.
Conclusion: Hyperinsulinemia, hyperandrogenemia, hypofibrinolysis, and hyperhomocysteinemia as well as APCR and factor V Leiden mu-
tations are associated with RPL in patients with PCOS.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: polycystic ovary syndrome (PCOS); recurrent pregnancy loss (RPL); thrombophilia1. Introduction
Polycystic ovary syndrome (PCOS) is one the most com-
mon endocrinopathies associated with obesity, oligomenorrhea
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http://dx.doi.org/10.1016/j.jcma.2013.01.009resistance, and infertility, with an estimated prevalence of
6.5e6.7% in women of reproductive age.1,2 PCOS is one of
the major causes of infertility worldwide and affects about
20% of infertile couples.3 Patients with PCOS have an
increased risk of first trimester spontaneous abortion ranging
from 25%4 to 73%,5 which is relatively high. Previous studies
have demonstrated that several factors account for this.
Velazquez et al6 showed that patients with PCOS experi-
ence an insulin-induced elevation of plasminogen activator
inhibitor activity (PAI-Fx; the most potent inhibitor ofhinese Medical Association. All rights reserved.
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risk of miscarriage. Thrombophilia is also an important risk
factor for abortion in those patients with PCOS. In this regard,
previous studies have demonstrated that factor V Leiden-
associated thrombophilia,7,8 heterozygosity for prothrombin
factor mutations,9 and homozygosity for methylene tetrahy-
drofolate reductase gene (MTHFR) mutations10 are other
causes of miscarriage in patients with PCOS. In the same way,
deficiencies of some proteins, including protein C, protein S,
and antithrombin III, are also associated with pregnancy
complications and miscarriage.11
Thrombophilia is a multigenetic disorder due to either ac-
quired coagulation abnormalities (antiphospholipid anti-
bodies) or inherited coagulation abnormalities (deficiencies of
the natural anticoagulant proteins antithrombin, protein C or
protein S, factor V Leiden, and prothrombin G20210A), or to
the metabolic abnormality of hyperhomocysteinemia.12 In
women with recurrent pregnancy loss (RPL), screening reveals
a higher than normal incidence of polycystic ovaries.13 Hence,
a high level of fetal loss is characteristic not only of women
with RPL with thrombophilia, but also of women with PCOS.
It is postulated that the patient’s familial thrombophilia,
perhaps augmented by the endocrinopathy of PCOS, is asso-
ciated with failure of embryo transfers and miscarriages.14
Several studies have investigated the prevalence of so-
called mutations and serologic abnormalities of thrombo-
philia in patients with PCOS, but data regarding the role of
these mutations and serologic abnormalities in the pathogen-
esis of RPL in PCOS patients are still scarce. Thus, we per-
formed this study in order to shed light on the pathogenesis of
RPL in patients with PCOS and its association with
thrombophilias.
2. Methods2.1. Study design and subjectsThis caseecontrol comparative study was carried out in
2009, at the infertility clinic of Zeinabieh Hospital, a tertiary
care center affiliated to the Shiraz University of Medical
Sciences. We included four groups of patients in this study.
The first group comprised 60 patients with PCOS and RPL
(Group 1), while the second group included 60 patients with
RPL only (Group 2) selected from those referred to our center
for treatment of infertility. The third group was made up of 60
patients with PCOS alone (Group 3), and the fourth group
comprised 60 controls (Group 4). Participants in each of the
four study groups were matched regarding age, body mass
index, and parity. The study was approved by the review board
and ethics committee of Shiraz University of Medical Sci-
ences, and informed consent forms were signed by all
participants.
RPL was defined as three or more consecutive pregnancy
losses at less than 20 weeks of gestation. Pregnant women and
those with a history of abortion or major surgery during the
previous 5 months, as well as those who had had a recent
myocardial infarction, had received aspirin or heparin in thelast 15 days, were receiving sex steroid therapy or combined
oral contraceptives, or had a history of hematologic, malignant
liver, or thromboembolic disease were excluded from the
study. Other causes of RPL including chromosomal and
uterine abnormalities and antiphospholipid syndrome were
ruled out. Inflammatory, autoimmune, and any other condition
affecting homeostasis were ruled out by either physical ex-
amination or patient history. None of the subjects were
smokers and none consumed alcohol.
PCOS has been defined according to the European Society
of Human Reproduction and Embryology/American Society
for Reproductive Medicine PCOS consensus workshop.15 By
this definition, all patients had at least two of the three
following criteria: (1) chronic anovulation, (2) clinical and/or
biochemical evidence of androgen excess, and (3) polycystic-
appearing ovaries observed on transvaginal ultrasound scan-
ning. Patients with Cushing’s syndrome, hyperprolactinemia,
diabetes mellitus, thyroid disease, adrenal hyperplasia and
androgen-secreting tumors, or other endocrinopathies were
excluded from the study. Patients with adrenal hyperplasia
were excluded if adrenocorticotrophic hormone (ACTH)-
stimulated 17-hydroxyprogesterone levels were less than
10 ng/mL,16 and if ACTH-stimulated 11-deoxycortisol levels
were less than 21 ng/mL (3 times the 95th percentile17 of a
historical control group of 60 healthy female controls).
Venepuncture was performed on the 10th day of the men-
strual cycle following overnight fasting. Withdrawn blood was
placed in a container with trisodium citrate (3.8 g/dL) in a
proportion of 9:1. The citrated blood was centrifuged at
3500 rpm for 10 minutes at room temperature, and then
plasma was collected and frozen at 80 C using liquid ni-
trogen until testing. Before the final test, the plasma was
thawed in a water basin for 15 minutes at a temperature of
37 C. EDTA-anticoagulant samples were used for DNA
analysis, and genomic DNAwas prepared from blood samples
according to standard methods.2.2. Hormonal, serologic, and genetic assaysHormonally related assays included serum follicle-
stimulating hormone (FSH), luteinizing hormone (LH), total
testosterone, dehydroepiandrosterone sulfate (DHEAS), ho-
mocysteine (Hcy), fasting blood sugar (FBS), and fasting in-
sulin. Insulin sensitivity was assessed by the Quantitative
Insulin Sensitivity Check Index (QUICKI), defined as 1/[log(-
fasting insulin) þ log(fasting glucose)].18 Participants were
diagnosed as having insulin resistance when the ratio of fasting
glucose to fasting insulin was less than 4.5.19 All the hormonal
assays were performed at the Endocrinology and Metabolism
Research Center of Nemazee Hospital. Serum FSH (FSH-
IRMA, KIP0264; Biosource, Nivelles, Belgium), LH (LH-
IRMA CT, REF KP7CT; Radim, Rome, Italy), and DHEAS
(DHEA-S-IRMA, KIP0481; Biosource) were measured by
immunoradiometric assay. Serum testosterone levels were
measured with radioimmunoassay (ESTO-RIA-CT, KIP1709;
Biosource). The total fasting Hcy plasma concentration was
determined using an enzyme conversion immunoassay kit
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efficients of variation were <6% for all assays performed.
All the serologic and genetic assays were performed at the
Hematology Research Center of Dastgheib Hospital. Chro-
mogenic assay was used to determine the functional capacity
of antithrombin III (HemosIL, Lot 574094; Lexington, MA,
USA) and protein C activity (HemosIL, Lot 185659), and total
protein S was measured using a protein S clotting assay kit
(HemosIL, Lot 285835). At that time, PAI-Fx was also
measured. Before the last test for activated protein C resis-
tance was undertaken, plasma was initially mixed with factor
V-deficient plasma, and then the activated partial thrombo-
plastin time was measured in response to activated protein C
and also in the absence of this agent. A Pro APC kit
(HemosIL, Lot N1175277) was used for this purpose, and the
APC ratio (APCR) was calculated as the ratio of the clotting
times obtained in the presence and absence of activated protein
C. Values less than 1.9 were considered to indicate resistance
to activated protein C. The clotting assays were performed on
an IL instrument (Beckman/Instrumentation Laboratory ACL
9000 - Coagulation Analyzer; MYCO Instrumentation, Inc.;
Renton, Washington, USA).2.3. Factor V Leiden analysisA 287-bp fragment of the factor V gene containing the base
pair 1691G/A was amplified using the polymerase chain re-
action (PCR).20 Digestion of the PCR products containing the
wild-type, heterozygous, and homozygous alleles with the re-
striction enzymeMnlI resulted in 37-, 93-, and 157-bp; 157-, 130-
, 93-, and 37-bp; and 157- and 130-bp fragments, respectively.2.4. Prothrombin G20210A analysisA 345-bp fragment of the prothrombin gene containing the
base pair 20210G/Awas amplified using PCR.9 Digestion of
the PCR products containing the wild-type, heterozygous, and
homozygous alleles with the restriction enzyme HindIII
resulted in 345-bp; 345-, 322-, and 23-bp; and 322- and 23-bp
fragments, respectively2.5. MTHFR analysisA 198-bp fragment of the MTHFR gene containing base
pair 677C/T was amplified using PCR.21 Digestion of the
PCR products containing the wild-type, heterozygous, and
homozygous alleles with the restriction enzyme HinfI resulted
in 345-bp; 345-, 322-, and 23-bp; and 322- and 23-bp frag-
ments, respectively.2.6. Statistical analysisThe Statistical Package for the Social Sciences, SPSS for
Windows, version 15.0 (SPSS, Chicago, IL, USA) was used for
data analysis. It was estimated that a sample size of at least 53
individuals per group was needed to detect a significant dif-
ference, with a power of 0.8 and an a risk of 0.05.We decided toinclude 60 subjects per group in order to compensate for non-
evaluable patients. Overall differences among group means
were compared using one-way analysis of variance (ANOVA),
and comparisons between groups were performed by pairwise
comparison within the ANOVAmodel. The Bonferroni test was
used as a post hoc test with ANOVA. Categorical variables were
analyzed using the c2 or Fisher’s exact tests where applicable.
Data are reported as mean standard deviation and percentage
where appropriate. A two-sided p value <0.05 was considered
statistically significant.
3. Results
Overall, 240 individuals in four study groups were
included. Table 1 compares the demographic, hormonal, and
metabolic characteristics of the four study groups. All the
individuals were nulliparous. Patients in Group 1 had signifi-
cantly higher levels of testosterone ( p ¼ 0.026) and DHEAS
( p ¼ 0.035) compared to Group 3. In a similar manner, higher
levels of Hcy were detected in subjects in Group 1 than in
Group 3 ( p ¼ 0.036). Patients in Group 1 had significantly
higher levels of FBS ( p ¼ 0.041) and fasting insulin
( p ¼ 0.015), as well as lower insulin sensitivity measured by
QUICKI ( p ¼ 0.024), compared to Group 3. Levels of PAI-Fx
were also significantly higher in Group 1 than in the other
groups ( p ¼ 0.001, p ¼ 0.008, and p < 0.001, respectively). In
the same way, PAI-Fx was significantly higher in Group 2 than
in Group 4 ( p ¼ 0.018). However, there was no significant
difference between Group 2 and Group 4 regarding other
metabolic and hormonal parameters (Table 1).
Table 2 demonstrates the mean values for activated protein
proportions and APCR. There were no significant differences
between study groups regarding activated protein C, protein S,
and antithrombin III. However, patients in Group 1 had
significantly higher levels of APCR than those in Groups 3 and
4 ( p ¼ 0.009 and p ¼ 0.017, respectively). This finding was
also consistent with Group 2 ( p ¼ 0.008 and p ¼ 0.016,
respectively).
Table 3 shows the distribution of factor V Leiden, pro-
thrombin G20210A, and MTHFR mutations in the four study
groups. The prevalence of homozygous factor V Leiden was
found to be significantly higher in Group 1 than in Group 3
[odds ratio (OR) 5.8, 95% confidence interval (CI) 0.73e11.6;
p ¼ 0.001] or in Group 4 (OR 5.8, 95% CI 0.0.73e11.6;
p ¼ 0.001). These findings were also consistent in Group 2
compared to Group 3 (OR 7.25, 95% CI 1.23e14.7;
p < 0.001) and in Group 4 (OR 7.25, 95% CI 1.23e14.7;
p < 0.001). Heterozygosity of factor V Leiden was also higher
in Group 1 than in Group 4 (OR 3.85, 95% CI 0.34e8.1;
p ¼ 0.022). It was also higher in Group 2 than in Group 3 (OR
3.763, 95% CI 0.26e6.94; p ¼ 0.001) and Group 4 (OR 5.21,
95% CI 0.94e10.6; p < 0.001). The prevalence of pro-
thrombin G20210A and MTHFR was not found to be signifi-
cantly different between the four study groups. Neither
homozygosity nor heterozygosity of these two genes increased
the risk of RPL in the four study groups. The risk of hetero-
zygosity of MTHFR was 1.5-fold higher in Group 1 compared
Table 1
Demographic, hormonal, and metabolic characteristics of the four study groups.
PCOS with RPL
(Group 1; n ¼ 60)
RPL without PCOS
(Group 2; n ¼ 60)
PCOS without RPL
(Group 3; n ¼ 60)
Without PCOS and PRL
(Group 4; n ¼ 60)
pa
Age (y) 24.3  4.8 24.8  3.9 25.1  5.6 24.6  4.7 0.512
BMI (kg/m2) 28.3  2.1 27.5  1.3 29.6  2.3 27.1  3.5 0.098
Testosterone (ng/mL) 0.93  0.04 0.49  0.2b 0.71  0.09b,c 0.43  0.3b,d 0.031
LH (mIU/mL) 9.42  1.2 4.32  1.4b 8.94  1.03c 4.65  0.9b,d <0.001
FSH (mIU/mL) 6.31  1.5 4.98  1.2b 6.52  1.05c 5.23  1.4b,d 0.024
LH:FSH 1.48  0.64 0.86  0.41b 1.37  0.83c 0.89  0.72b,d 0.007
DHEAS (mg/dL) 321.5  78.1 208.3  36.8b 286.1  89.3b,c 216.8  24.9b,d <0.001
Hcy (mmol/L) 12.4  1.6 7.3  1.1b 9.65  0.9b,c 6.7  1.9b,d <0.001
PAI-Fx (U/mL) 20.3  2.9 11.8  3.6b 14.6  3.2b 8.4  2.1b,c,d <0.001
FBS (mg/dL) 91.3  6.57 76.3  8.66b 86.9  5.47c 77.3  5.8b,d 0.002
Fasting insulin (mU/mL) 19.1  4.13 15.3  3.75b 17.2  3.61b,c 14.3  2.91b,d <0.001
QUICKI 0.308  0.011 0.326  0.008b 0.316  0.004b,c 0.331  0.013b,d 0.004
Values are expressed as the mean  SD.
Significant difference between groups ( p < 0.05).
BMI ¼ body mass index; DHEAS ¼ dehydroepiandrostendione sulfate; FBS ¼ fasting blood glucose; FSH ¼ follicle-stimulating hormone; Hcy ¼ homocysteine;
LH ¼ luteinizing hormone; PAI-Fx ¼ plasminogen activator inhibitor activity; PCOS ¼ polycystic ovary syndrome; QUICKI ¼ Quantitative Insulin Sensitivity
Check Index; RPL ¼ recurrent pregnancy loss.
a All p values have been calculated by one-way analysis of variance.
b Significant difference when compared to Group 1 ( p < 0.05).
c Significant difference when compared to Group 2 (p < 0.05).
d Significant difference when compared to Group 3 (p < 0.05).
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0.24e7.58; p ¼ 0.342).
4. Discussion
Several previous studies have demonstrated the role of both
inherited and acquired thrombophilia in RPL.7,11,12 These
disorders increase the risk of thrombosis, and thus increase the
risk for RPL.11,12 Previous studies have also demonstrated that
the risk of miscarriage and RPL is significantly higher among
patients with PCOS.3,4,13,14 In other words, it seems that pa-
tients with PCOS have an increased risk for both abortion and
RPL. Some previous studies have examined this issue.14,22,23
However, the power of this study lies in its four-group
design, which can shed light on some of the more difficult
components of this subject.
In this study, we tried to investigate the role of hyper-
androgenemia, insulin resistance, and hyperhomocysteinemia
as well as inherited and acquired thrombophilias in patientsTable 2
Activated protein proportions and activated protein C ratio (APCR) in the two stu
PCOS with RPL
(Group 1; n ¼ 60)
RPL without PCOS
(Group 2; n ¼ 60)
Protein S 99.7  17.8 98.4  25.9
Protein C 114.1  20.2 109.9  26.7
Antithrombin III 100.6  13.1 104.5  12.3
APCR 2.89  0.34 2.89  0.16
Values are expressed as the mean  standard deviation.
Significant difference between groups ( p < 0.05).
PCOS ¼ polycystic ovary syndrome; RPL ¼ recurrent pregnancy loss.
a All p values have been calculated by one-way analysis of variance.
b Significant difference when compared to Group 1 ( p < 0.05).
c Significant difference when compared to Group 2 ( p < 0.05).with PCOS who had RPL. We found that patients with PCOS
and RPL had higher testosterone, DHEAS, and Hcy levels than
patients without PCOS but with RPL. RPL in those patients
with PCOS was also associated with hypofibrinolysis
(measured by PAI-Fx) and decreased insulin sensitivity
(measured by QUICKI). We also observed higher levels of
Hcy in patients with RPL than in healthy individuals.
Some previous studies have investigated the role of
hyperandrogenemia and insulin resistance in the pathogenesis
of RPL in PCOS patients.22,24 Tsanadis et al24 demonstrated
that patients with both PCOS and RPL had higher levels of
testosterone, estradiol, sex hormone binding globulin, prolac-
tin, and FSH, and lower levels of LH, compared to those
without PCOS. However, the level of DHEAS did not differ
between the two groups. Taking all of these factors into
consideration, it can be concluded that hyperandrogenemia is
associated with RPL in patients with PCOS.
We further showed that fasting insulin level and FBS were
also higher in those with PCOS and RPL compared to thosedy groups.
PCOS without RPL
(Group 3; n ¼ 60)
Without PCOS and PRL
(Group 4; n ¼ 60)
pa
102.8  15.7 103.7  26.4 0.088
116.6  19.5 115.4  28.4 0.514
105.7  13.4 104.9  16.3 0.627
2.57  0.09b,c 2.61  0.22b,c 0.014
Table 3
Distribution of factor V Leiden, prothrombin G20210A, and methylene tetrahydrofolate reductase (MTHFR) mutations in four study groups.
PCOS with RPL
(Group 1; n ¼ 60)
(n, %)
RPL without PCOS
(Group 2; n ¼ 60)
(n, %)
PCOS without RPL
(Group 3; n ¼ 60)
(n, %)
Without PCOS and PRL
(Group 4; n ¼ 60)
(n, %)
pa
Factor V Leiden
Homozygous (GG) 4 (6.7) 5 (8.3) 2 (3.3)b,c 2 (3.3)b,c 0.031
Heterozygous (AG) 8 (13.3) 12 (20) 6 (10)c 4 (6.7)b,c 0.068
Wild-type (AA) 48 (80) 43 (71.7) 52 (86.7) 54 (90) 0.072
Prothrombin G20210A
Homozygous (GG) 2 (3.3) 0 (0) 0 (0) 0 (0) 0.831
Heterozygous (AG) 2 (13.3) 8 (13.3) 4 (6.7) 6 (10) 0.564
Wild-type (AA) 50 (83.4) 42 (86.7) 56 (93.3) 54 (90) 0.327
MTHFR
Homozygous (TT) 4 (6.6) 4 (6.6) 0 (0) 2 (3.3) 0.158
Heterozygous (CT) 8 (13.3) 6 (10) 6 (10) 6 (10) 0.731
Wild-type (CC) 48 (80.1) 50 (83.4) 54 (90) 54 (86.7) 0.094
Values are proportions (%).
Significant difference between groups ( p < 0.05).
a All p values have been calculated by the c2 test.
b Significant difference when compared to Group 1 ( p < 0.05).
c Significant difference when compared to Group 2 ( p < 0.05).
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et al.24 Insulin sensitivity was also significantly lower in these
patients. By contrast, Glueck et al25,26 showed that adminis-
tering metformin during pregnancy improves the pregnancy
outcomes of patients with PCOS. These findings indicate that
a combination of insulin resistance and hyperandrogenemia is
responsible for poor pregnancy outcome in those with PCOS.
As metformin reduces insulin resistance as well as hyper-
androgenemia27 in patients with PCOS, it can improve preg-
nancy outcome, as has been shown in previous studies.5,26
We found higher levels of Hcy in those with PCOS and
RPL compared to those PCOS patients without RPL, sug-
gesting a role for Hcy in the pathogenesis of RPL in patients
with PCOS. Balasa et al28 demonstrated that patients with
mutations in MTHFR have higher plasma levels of Hcy.
However, MTHFR mutations are responsible for inherited
thrombophilia and RPL.
In this study, we showed that the risk of heterozygosity of
MTHFR was 1.5-fold higher in those patients with PCOS and
RPL compared to the group with PCOS, although this was not
significant. However, more individuals were homozygous and
heterozygous for MTHFR (6 patients) among these patients
compared to the PCOS group (3 patients), and thus the preva-
lence of mutant allele T was higher (19.9% vs. 8.3%). Conse-
quently, higher levels of Hcy in these patients may be due to a
higher prevalence of MTHFR mutations in these groups of
patients. Hyperinsulinemia influences Hcy metabolism through
different mechanisms, including effects on glomerular filtration
or an influence on the activity of key enzymes in Hcy meta-
bolism.29 Hcy can directly damage endothelial cells, impairing
the release of nitric oxide and leading to a net increase in the
production of superoxide. Thus, hyperhomocysteinemia can
also be secondary to insulin resistance and arise as a result of
the metabolic changes of PCOS itself.
We also observed hypofibrinolysis (measured by PAI-Fx) in
patients with PCOS and RPL compared to those without RPL,with PCOS incidence rates consistent with those of previous
studies.22,23 PAI-Fx rises with increasing levels of serum in-
sulin and decreases when insulin is reduced by metformin.23,25
Hypofibrinolysis, associated with the 4G/4G polymorphism of
the PAI-1 gene,30 is associated with poor pregnancy outcome
as well as second and third trimester complications. High
levels of PAI-Fx (reflecting the product of the PAI-1 gene) are
related to spontaneous abortion, and PCOS is associated with
insulin-induced high PAI-Fx levels.5,6
Our study revealed a higher proportion of APCR in patients
with RPL with and without PCOS compared to other groups.
However, we did not find any association between proteins C
and S and antithrombin III and RPL in any of the study groups,
which is consistent with findings from previous studies.22,24
Proteins C and S are plasma vitamin K-dependent proteins,
while antithrombin III is a vitamin K-independent plasma
protein; all these proteins are synthesized by the liver. Acti-
vated protein C binds protein S and inactivates coagulation
factors Va and VIIIa, limiting further coagulation. Protein C
and protein S deficiencies will lead to inadequate degradation
of factors Va and VIIIa and progression of the hyper-
coagulatory status.31 As activated protein C resistance is
associated with factor V Leiden, higher proportions of APCR
in the PCOS with RPL group can be explained by the higher
prevalence of factor V Leiden mutations in this group.
Gene analysis revealed that factor V Leiden mutations are
associated with an increased risk of RPL in patients with and
without PCOS. Similarly, Behjati et al32 showed that the fre-
quency of factor V Leiden mutations in patients with infertility
(30.6%) or recurrent spontaneous abortion (20.0%) was
significantly higher than that of the control group. Contrary to
our findings are results from Tsanadis et al,24 who found no
difference between patients with and without PCOS regarding
factor V Leiden mutations. However, we failed to find an as-
sociation between prothrombin G20210A and MTHFR muta-
tions and RPL in both patients with and without PCOS.
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zygosity increased 1.5-fold in the PCOS with RPL group,
although not significantly. These findings are consistent with
those of previous studies.22,24 We did not evaluate other pre-
viously mentioned mutations, including factor V A1299H
(A4070G) and MTHFR A1298C, which is thought to be
associated with RPL in patients with PCOS; this is a limitation
of our study.
In summary, patients with PCOS who have RPL have
increased levels of serum testosterone, DHEAS, Hcy, insulin,
and PAI-Fx, and decreased insulin sensitivity. They also have
higher proportions of APCR and a higher prevalence of factor
V Leiden mutations compared to PCOS patients without RPL.
As discussed above, hyperinsulinemia and insulin resistance is
the key step in the pathogenesis of RPL in patients with PCOS.
Hyperinsulinemia not only induces hyperandrogenemia in
these patients, but also induces hypofibrinolysis (by increasing
serum levels of PAI-Fx) and hyperhomocysteinemia; in turn,
all of these increase the risk of RPL. However, inherited
mutations of factor V Leiden and MTHFR cause APCR and
hyperhomocysteinemia, and thus increase the risk for RPL. A
combination of these mechanisms can explain the higher
prevalence of RPL in patients with PCOS.
In conclusion, hyperinsulinemia, hyperandrogenemia,
hypofibrinolysis, and hyperhomocysteinemia as well as APCR
and factor V Leiden mutations are associated with RPL in
patients with PCOS.Acknowledgments
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